Isaac Baiden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isaac Baiden has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Akinlolu Oluwamisimi1 shared publication
- Chidinma Lorretta Gab-Obinna
Biomedical Laboratory Science Department, Kingston University London, London, United Kingdom
1 shared publication - Daniel Obinna Eke
Department of Nursing, Myrtle E. and Earl E. Walker College of Health Professions Maryville University of St. Louis, St. Louis, MO, USA
1 shared publication - Gifty Dudzilah
Department of Physical Science, Eastern New Mexico University, Portales, New Mexico, USA
1 shared publication - Ndidi Atasie Eboh
Department of Nursing Science, Stark State College, North Canton, OH, USA
1 shared publication Samuel Okpure Phil-Othihiwa
Bestcare Hospital, Lagos, Nigeria
1 shared publication
Latest Publications
- Open Access
- 3 February 2026
- Published by Stecab Publishing
- Vol. 1 (1) , 10-18
Digital Biomarkers for Early Cognitive Decline: Clinical Promise, Limitations, and Validation Pathways
There is increasing global concern regarding the growing burden of cognitive decline and dementia, particularly because existing diagnostic tools often fail to detect subtle preclinical changes. Early detection is critical to enable timely intervention, yet these limitations hinder effective clinical management and opportunities to slow disease progression, underscoring the need for complementary methods that provide objective, continuous, and sensitive measures of cognitive function. Digital biomarkers, defined as quantifiable metrics derived from mobile devices, online technologies, and wearable sensors, offer a promising approach for enhancing early detection when integrated with traditional cognitive assessments and biological markers. This report critically reviews digital biomarkers across multiple domains, including speech, behavior, cognition, and motor function, and evaluates their capacity to identify early cognitive alterations. Key challenges related to clinical integration, study design, analytical methods, standardization, and consistency of practice are examined, alongside the advantages of multimodal and longitudinal assessment approaches. While digital biomarkers have demonstrated sensitivity to subtle cognitive changes, significant operational, methodological, and validation challenges remain, particularly with respect to reproducibility, accessibility, and equity. By providing a balanced synthesis of the clinical promise and current limitations of digital biomarkers, this review aims to inform future research priorities, support rigorous validation pathways, and guide the development of clinically useful, ethically designed, and validated digital tools for the early monitoring of cognitive decline.
- 3 February 2026
- Published by Stecab Publishing
- Vol. 1 (1) , 10-18
Open AccessDigital Biomarkers for Early Cognitive Decline: Clinical Promise, Limitations, and Validation Pathways
There is increasing global concern regarding the growing burden of cognitive decline and dementia, particularly because existing diagnostic tools often fail to detect subtle preclinical changes. Early detection is critical to enable timely intervention, yet these limitations hinder effective clinical management and opportunities to slow disease progression, underscoring the need for complementary methods that provide objective, continuous, and sensitive measures of cognitive function. Digital biomarkers, defined as quantifiable metrics derived from mobile devices, online technologies, and wearable sensors, offer a promising approach for enhancing early detection when integrated with traditional cognitive assessments and biological markers. This report critically reviews digital biomarkers across multiple domains, including speech, behavior, cognition, and motor function, and evaluates their capacity to identify early cognitive alterations. Key challenges related to clinical integration, study design, analytical methods, standardization, and consistency of practice are examined, alongside the advantages of multimodal and longitudinal assessment approaches. While digital biomarkers have demonstrated sensitivity to subtle cognitive changes, significant operational, methodological, and validation challenges remain, particularly with respect to reproducibility, accessibility, and equity. By providing a balanced synthesis of the clinical promise and current limitations of digital biomarkers, this review aims to inform future research priorities, support rigorous validation pathways, and guide the development of clinically useful, ethically designed, and validated digital tools for the early monitoring of cognitive decline.
- 1 January 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (1) , 310-329
Integrating Social Determinants of Health into Precision Medicine: A Critical Review of a Missing Link in Personalized Healthcare
Background: Precision medicine has transformed healthcare through advances in genomics, biomarkers, and artificial intelligence. However, its predominant focus on biological determinants reflects a reductionist approach that inadequately captures the broader social and environmental factors influencing health outcomes. Aim: This review aims to critically examine the limitations of current precision medicine frameworks, particularly the exclusion of social determinants of health (SDOH), and to explore the need for a more integrative, context-aware approach to personalized healthcare. Methods: A critical narrative review was conducted using literature from PubMed, Scopus, and Web of Science, covering publications between 2015 and 2025. Relevant studies addressing precision medicine, SDOH, health disparities, and artificial intelligence were selected based on predefined inclusion criteria and analyzed using thematic synthesis. Results: The findings reveal that current precision medicine models are constrained by biological reductionism, data bias, algorithmic inequities, and fragmented data systems. The exclusion of SDOH limits predictive accuracy, reduces the effectiveness of personalized interventions, and contributes to persistent health disparities. Emerging evidence highlights the potential of integrating artificial intelligence and digital health technologies with social and behavioral data to enhance context-aware care. Conclusion: Precision medicine, as currently practiced, is biologically precise but contextually incomplete. Integrating SDOH into precision medicine frameworks is essential for improving clinical effectiveness, promoting health equity, and ensuring real-world applicability. A shift toward an integrative model that combines biological, social, and behavioral determinants is necessary to achieve truly personalized and patient-centered healthcare.
- 1 January 2026
- Published by IK Press in Journal of Medicine and Health Research
- Vol. 11 (1) , 310-329
Integrating Social Determinants of Health into Precision Medicine: A Critical Review of a Missing Link in Personalized Healthcare
Background: Precision medicine has transformed healthcare through advances in genomics, biomarkers, and artificial intelligence. However, its predominant focus on biological determinants reflects a reductionist approach that inadequately captures the broader social and environmental factors influencing health outcomes. Aim: This review aims to critically examine the limitations of current precision medicine frameworks, particularly the exclusion of social determinants of health (SDOH), and to explore the need for a more integrative, context-aware approach to personalized healthcare. Methods: A critical narrative review was conducted using literature from PubMed, Scopus, and Web of Science, covering publications between 2015 and 2025. Relevant studies addressing precision medicine, SDOH, health disparities, and artificial intelligence were selected based on predefined inclusion criteria and analyzed using thematic synthesis. Results: The findings reveal that current precision medicine models are constrained by biological reductionism, data bias, algorithmic inequities, and fragmented data systems. The exclusion of SDOH limits predictive accuracy, reduces the effectiveness of personalized interventions, and contributes to persistent health disparities. Emerging evidence highlights the potential of integrating artificial intelligence and digital health technologies with social and behavioral data to enhance context-aware care. Conclusion: Precision medicine, as currently practiced, is biologically precise but contextually incomplete. Integrating SDOH into precision medicine frameworks is essential for improving clinical effectiveness, promoting health equity, and ensuring real-world applicability. A shift toward an integrative model that combines biological, social, and behavioral determinants is necessary to achieve truly personalized and patient-centered healthcare.